Recent Updates
Recently added Catalysts

Physical exercise

Phase 3

Breast Cancer | Unknown | Oncology |Avalon GloboCare Corp.|Last Updated: Jul 18, 2016

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment301

FDA Designations

No designations recorded

Clinical trial landscape

Physical exercise · 1 trial · 1 indication

Phase 3 1
NCT00249015Trial of Combined Aerobic and Resistance Exercise in Breast Cancer SurvivorsBreast Cancer
COMPLETED301 Analytics
PHASE3COMPLETED
Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors
Breast CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Patient rated physical functioning
at 8 weeks and 24 weeks

Secondary Endpoints

Physical fitness, body composition, treatment completion rates, exercise adherence rates, adverse events
at 8 weeks and 24 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelSINGLE_GROUP

Treatment Arms

ArmTypeDescription
1EXPERIMENTALCombined Aerobic and Resistance Exercise Program: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity as well as some weight training consisting of two sets of 8-12 repetitions of 9-10 different exercises. For the aerobic exercise, participant can choose from different exercise equipment such as a treadmill or stationary bicycle.
2ACTIVE_COMPARATORModerate Aerobic Exercise Group: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
3EXPERIMENTALHigh Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.

Interventions

NameTypeDescription
Physical exerciseBEHAVIORALperform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites1

* Are diagnosed with stage I-IIIA breast cancer, histologically confirmed * Are scheduled to receive adjuvant chemotherapy (receiving neoadjuvant chemotherapy for locally advanced cancer is an exclusion criteria) * Have not received previous chemotherapy (previous cancer is NOT an exclusion criteria...

Countries:Canada
Unlock Eligibility Criteria

Competitive Landscape -Breast Cancer 402 trials

Top 20 of 92 competitors

CompanyTickerTrialsLead PhaseDrugs
AstraZeneca PLCAZN47PHASE3Fulvestrant, Capivasertib
Merck & Co., Inc.MRK12PHASE3Pembrolizumab, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide
Eli Lilly and CompanyLLY27PHASE3Abemaciclib, Standard Adjuvant Endocrine Therapy
BioNTech SE Sponsored ADRBNTX7PHASE3DB-1303/BNT323, T-DM1
Gilead Sciences, Inc.GILD13PHASE3Sacituzumab Govitecan-hziy, Eribulin, Capecitabine Product, Gemcitabine, Vinorelbine
Novartis AG Sponsored ADRNVS30PHASE3Ribociclib
Pfizer Inc.PFE34PHASE3ARV-471, Fulvestrant
BeOne Medicines Ltd. Sponsored ADRONC5PHASE3BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib
Olema Pharmaceuticals, Inc.OLMA5PHASE3Palazestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane
Jazz Pharmaceuticals Public Limited CompanyJAZZ3PHASE3Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine
Celcuity Inc.CELC3PHASE3Gedatolisib, Palbociclib, Fulvestrant, Alpelisib
Relay Therapeutics, Inc.RLAY2PHASE3Zovegalisib, Capivasertib, Fulvestrant
GSK plc Sponsored ADRGSK2PHASE3Niraparib
Greenwich LifeSciences, Inc.GLSI1PHASE3GLSI-100
Bristol-Myers Squibb CompanyBMY5PHASE2Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin
BriaCell Therapeutics CorpBCTX2PHASE3SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
Incyte CorporationINCY4PHASE2Ruxolitinib, Capecitabine, Regorafenib
Natera, Inc.NTRA3PHASE2Discontinuation of the anti-HER2 maintenance therapy
Puma Biotechnology, Inc.PBYI3PHASE2Neratinib, Loperamide, Colesevelam
Atossa Therapeutics, Inc.ATOS1PHASE2endoxifen, goserelin
Unlock Competitive Intelligence

Frequently asked questions about Physical exercise

What is Physical exercise used for in Breast Cancer?

Physical exercise is being studied as an intervention for breast cancer survivors. A Phase 3 clinical trial evaluated the effects of combined aerobic and resistance exercise in this population. The study enrolled 301 female participants aged 18 years and older in Canada and has been completed.

Who makes Physical exercise?

Physical exercise is being developed by Avalon GloboCare Corp., a company listed on the stock exchange under the ticker ALBT. The company is conducting clinical research to evaluate the potential benefits of exercise as an intervention for breast cancer survivors.

What phase is Physical exercise in?

Physical exercise is in Phase 3 clinical development for breast cancer. One Phase 3 trial has been completed, which enrolled 301 participants. The study was randomized and active-controlled, meaning it compared the exercise intervention against an active control group.

What clinical trials is Physical exercise in?

Physical exercise has one completed clinical trial registered under NCT00249015, titled 'Trial of Combined Aerobic and Resistance Exercise in Breast Cancer Survivors.' This Phase 3 study enrolled 301 female participants in Canada and evaluated the intervention's effects in breast cancer survivors.

Is Physical exercise FDA approved?

Physical exercise is an investigational intervention still in clinical development for breast cancer. It has completed a Phase 3 trial, but approval status has not been established. The intervention remains under study and is not confirmed as an approved treatment.